GenEdit is developing genetic medicines with targeted in vivo delivery based on the NanoGalaxy® platform of non-viral, non-lipid hydrophilic nanoparticles (HNPs). HNPs offer a combination of advantages, including tissue selectivity, payload flexibility (siRNA, mRNA, gene editors up to 10 kB), low immunogenicity, ability to re-dose and ease of manufacturing. GenEdit identified HNPs that deliver to multiple tissues and cells such as antigen presenting cells in the spleen, neurons and glial cells in the brain or endothelium of the lung. GenEdit aims to leverage the full potential of the versatile HNP platform through the development of internal program to treat neurological diseases -currently in discovery stage- and partnerships in immunology, neurology and other therapeutic areas. GenEdit announced a multiyear collaboration and license agreement with Genentech to develop novel nanoparticles to deliver genetic medicines for autoimmune disease (January, 2023).